公开(公告)号：US11899025B2

公开(公告)日：2024-02-13

申请号：US16982494

申请日：2019-03-21

申请人： KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

发明人： Jae-Sung Bae ,  Hee Kyung Jin ,  Ju Youn Lee ,  Seung Hoon Han

IPC分类号： G01N33/68 ,  G01N33/50 ,  G01N33/573 ,  A61K31/164

CPC分类号： G01N33/6896 ,  A61K31/164 ,  G01N33/5008 ,  G01N33/573 ,  G01N2333/90241 ,  G01N2440/10

摘要： The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a COX2 acetylating agent as an active ingredient and, more particularly, to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising, as an active ingredient, a COX2 acetylating agent which exhibits an effect of inhibiting the deposition of amyloid-β in brain neurons, reducing excessive neuroinflammatory responses, and increasing the phagocytosis of amyloid-β in microglial cells. The pharmaceutical composition for preventing or treating neurodegenerative diseases comprising the COX2 acetylating agent as an active ingredient has the effects of alleviating neuroinflammation by promoting COX2 acetylation in neurons and secreting specialized pro-resolving mediators (SPMs) and thus, can be very useful in the development of a preventive or therapeutic agent for neurodegenerative diseases.

公开(公告)号：US20240125804A1

公开(公告)日：2024-04-18

申请号：US18395097

申请日：2023-12-22

申请人： KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

发明人： Jae-Sung BAE ,  Hee Kyung Jin ,  Ju Youn Lee ,  Seung Hoon Han

IPC分类号： G01N33/68 ,  A61K31/164 ,  G01N33/50 ,  G01N33/573

CPC分类号： G01N33/6896 ,  A61K31/164 ,  G01N33/5008 ,  G01N33/573 ,  G01N2333/90241 ,  G01N2440/10

摘要： The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a COX2 acetylating agent as an active ingredient and, more particularly, to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising, as an active ingredient, a COX2 acetylating agent which exhibits an effect of inhibiting the deposition of amyloid-β in brain neurons, reducing excessive neuroinflammatory responses, and increasing the phagocytosis of amyloid-β in microglial cells. The pharmaceutical composition for preventing or treating neurodegenerative diseases comprising the COX2 acetylating agent as an active ingredient has the effects of alleviating neuroinflammation by promoting COX2 acetylation in neurons and secreting specialized pro-resolving mediators (SPMs) and thus, can be very useful in the development of a preventive or therapeutic agent for neurodegenerative diseases.